Skip to main content
. Author manuscript; available in PMC: 2014 Jan 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2012 Nov 16;266(2):317–327. doi: 10.1016/j.taap.2012.11.009

Figure 8. Increased adhesion molecule expression and the effect of neutralization of CD18 on TCDD/Con A-mediated liver injury.

Figure 8

(A) Mice were treated as described in the legend to Figure 2 with Vehicle/Saline, TCDD/Saline, Vehicle/Con A or TCDD/Con A. Liver samples were collected 6 h after Saline or Con A treatment, and hepatic ICAM-1 mRNA expression was determined by RT-PCR. a p < 0.05 TCDD/Con A versus TCDD/Saline. b p < 0.05 Vehicle/Con A versus Vehicle/Saline. c p < 0.05 TCDD/Con A versus Vehicle/Con A. Data represent the mean ± SE of 6 independent replicates. (B) Mice were treated with vehicle or TCDD on day 0 then administered either CD18 antiserum (striped bars) or normal rabbit serum (NRS)(open bars) 15 h prior to treatment with 6 mg/kg Con A. A second administration of CD18 antiserum or NRS was given 2 h after Con A. ALT activity in plasma was measured 24 h after Con A administration. c p < 0.05 TCDD/Con A versus Vehicle/Con A within the same pre-treatment. f p < 0.05 versus the same treatment group with normal rabbit serum pretreatment. Data represent the mean ± SE of independent replicates from 2 separate experiments. For each treatment group: Vehicle/Saline n=6, TCDD/Saline n=6, Vehicle/Con A n=4-6, TCDD/Con A n=4–6.